The delegation, including representatives from startups, non-profits, and established corporations, reflects the breadth of regional development. Among the highlighted organizations is Prenosis, a biology-based company recognized for its pioneering work in precision therapeutics. Luke Tanen, President and CEO of Chicago Innovation, noted that these awardees represent the highest standard of product development, successfully addressing previously unmet needs across a variety of sectors.
Prenosis and Chicago Innovation Winners Ring the Nasdaq Opening Bell
On Monday, August 31, a coalition of Chicago’s most influential innovators will take center stage in New York City to mark the opening of the Nasdaq stock market. The event highlights the diverse economic landscape of the Chicago region, featuring winners of the 2025 Chicago Innovation Awards at the historic bell-ringing ceremony.
Prenosis earned its place on the stage by developing the Sepsis ImmunoScore, the first FDA-authorized AI diagnostic tool for sepsis. Built on the company’s proprietary Immunix platform, the technology analyzes biological and clinical data to provide real-time insights into immune responses, allowing clinicians to detect sepsis or its progression within a 24-hour window. CEO and co-founder Bobby Reddy, Jr. emphasized that the platform addresses the long-standing challenge of patient heterogeneity, which has historically hindered clinical trials for acute conditions like pneumonia and sepsis. By tailoring treatment to individual biology, the company aims to scale precision care for millions of patients annually.
Comments (0)
No comments yet. Be the first!